Search:

Filter:

Sort:

A Call to Action: Restoring and strengthening America’s patient safety system; protecting patients from the risks of mass drug compounding

June 25, 2026

PMS’s new report outlines solutions to protect patient safety in the growing compounded GLP-1 marketplace. A Call to Action: Restoring and Strengthening America’s Patient Safety System serves as a roadmap for policymakers and regulators to uphold the gold standard system that protects Americans from untested and unsafe medicines.

Partnership for Safe Medicines releases action plan to protect patients from unapproved compounded GLP-1s

June 25, 2026

PMS’s new report outlines solutions to protect patient safety in the growing compounded GLP-1 marketplace. A Call to Action: Restoring and Strengthening America’s Patient Safety System serves as a roadmap for policymakers and regulators to uphold the gold standard system that protects Americans from untested and unsafe medicines.

June 22, 2026: Study links alternative funding programs to treatment delays

June 24, 2026

AFPs, which often force patients to source medicines overseas, may present access concerns according to a new study.

Photo gallery, Gilead Sciences v Pain Relief Rx et al

June 23, 2026

Photo gallery, Gilead Sciences v Pain Relief Rx et al Examples of suspect product purchased from pharmacy-to-pharmacy online platforms in December 2025 and January 2026.

June 15, 2026: Colorado becomes the second state given federal approval for Canadian drug importation program

June 17, 2026

Similar importation programs have been plagued with logistical hurdles, despite extensive funding of the efforts.

Partnership for Safe Medicines statement on FDA authorization of Colorado’s Section 804 Importation Program

June 15, 2026

“Colorado is now poised to repeat Florida’s failed attempt to implement Canadian drug importation,” said PSM Executive Director Shabbir Imber Safdar. “Since beginning their program in 2019, Florida has spent $132 million and still not imported a single unit of medicine, proving that these bulk importation programs are not reducing drug costs for Americans.”

Fishy Peptide Freight: What Q1 2026 import data reveals

June 9, 2026

As the popularity of peptides skyrockets, consumers should be asking questions about where their drugs come from. Here’s what we found in shipment data for peptides in Q1.

June 8, 2026: Reckless physicians prescribing experimental, black market weight loss drugs: “Why are we waiting?”

June 9, 2026

Retatrutide, an experimental weight loss drug that hasn’t been submitted for FDA-approval, is being prescribed in weight loss clinics and med spas across the country.

Prescription Drug Freight Fraud, June 2026 report

June 9, 2026

March and April 2026 saw thousands of shipments of drugs imported into the US, including weight loss drugs and antibiotics. We studied these shipments to learn more about their manufacturers and contents.

Fake medicines in Mexico, November 2025 – May 2026

June 5, 2026

Americans buying prescription medicines in Mexico are overlooking widespread drug counterfeiting in the country, and as AFPs popularize medical tourism to lower costs, what happens in Mexico’s drug supply chain is even more of a problem for Americans.